Document And Entity Information
Document And Entity Information - shares | 6 Months Ended | |
Jun. 30, 2021 | Jul. 31, 2021 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0000088790 | |
Entity Registrant Name | INTRICON CORP | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Period Focus | Q2 | |
Document Fiscal Year Focus | 2021 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Jun. 30, 2021 | |
Document Transition Report | false | |
Entity File Number | 1-5005 | |
Entity Incorporation, State or Country Code | PA | |
Entity Tax Identification Number | 23-1069060 | |
Entity Address, Address Line One | 1260 Red Fox Road | |
Entity Address, City or Town | Arden Hills | |
Entity Address, State or Province | MN | |
Entity Address, Postal Zip Code | 55112 | |
City Area Code | 651 | |
Local Phone Number | 636-9770 | |
Title of 12(b) Security | Common stock, par value $1.00 per share | |
Trading Symbol | IIN | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 9,097,270 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Revenue, net | $ 30,215 | $ 23,602 | $ 61,983 | $ 45,105 |
Cost of goods sold | 22,343 | 16,996 | 45,901 | 33,927 |
Gross profit | 7,872 | 6,606 | 16,082 | 11,178 |
Operating expenses: | ||||
Sales and marketing | 2,021 | 1,680 | 4,003 | 3,673 |
General and administrative | 4,070 | 4,603 | 8,049 | 8,019 |
Research and development | 1,309 | 1,209 | 2,602 | 2,410 |
Other operating expenses (Note 11) | 1,415 | 0 | 1,523 | 0 |
Restructuring charges | 0 | 1,171 | 0 | 1,171 |
Acquisition costs | 0 | 493 | 0 | 493 |
Total operating expenses | 8,815 | 9,156 | 16,177 | 15,766 |
Operating loss | (943) | (2,550) | (95) | (4,588) |
Interest (expense) income, net | (14) | 97 | (23) | 281 |
Other (expense) income, net | (91) | 208 | (168) | 101 |
Loss before income taxes | (1,048) | (2,245) | (286) | (4,206) |
Income tax expense | 80 | 29 | 170 | 47 |
Net loss | (1,128) | (2,274) | (456) | (4,253) |
Less: Income allocated to non-controlling interest | 51 | 7 | 9 | 7 |
Net loss attributable to Intricon shareholders | $ (1,179) | $ (2,281) | $ (465) | $ (4,260) |
Loss per share attributable to Intricon shareholders: | ||||
Basic (in dollars per share) | $ (0.13) | $ (0.26) | $ (0.05) | $ (0.48) |
Diluted (in dollars per share) | $ (0.13) | $ (0.26) | $ (0.05) | $ (0.48) |
Average shares outstanding: | ||||
Basic (in shares) | 9,074 | 8,881 | 9,034 | 8,847 |
Diluted (in shares) | 9,074 | 8,881 | 9,034 | 8,847 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Net loss | $ (1,128) | $ (2,274) | $ (456) | $ (4,253) |
Unrealized foreign currency translation adjustment | 1 | 13 | 26 | 26 |
Realized pension and postretirement obligations | 12 | 5 | 24 | 10 |
Other | 68 | 0 | 183 | 0 |
Comprehensive loss | $ (1,047) | $ (2,256) | $ (223) | $ (4,217) |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 |
Current assets: | ||
Cash and cash equivalents | $ 6,077 | $ 8,608 |
Restricted cash | 658 | 672 |
Short-term investment securities | 23,022 | 19,793 |
Accounts receivable, net of $80 and $210 of reserves, respectively | 9,592 | 10,115 |
Inventories | 22,189 | 19,513 |
Contract assets | 11,618 | 9,107 |
Other current assets | 1,872 | 1,466 |
Total current assets | 75,028 | 69,274 |
Property, plant and equipment | 47,320 | 45,661 |
Less: Accumulated depreciation | 33,080 | 31,484 |
Net property, plant and equipment | 14,240 | 14,177 |
Goodwill | 13,873 | 13,714 |
Intangible assets, net | 9,791 | 10,785 |
Operating lease right-of-use assets, net | 5,782 | 6,701 |
Investment in partnerships | 592 | 570 |
Long-term investment securities | 3,794 | 5,085 |
Other assets, net | 987 | 990 |
Total assets | 124,087 | 121,296 |
Current liabilities: | ||
Current financing leases | 7 | 21 |
Current operating leases | 2,027 | 2,156 |
Accounts payable | 10,102 | 8,670 |
Accrued salaries, wages and commissions | 4,438 | 3,581 |
Other accrued liabilities | 6,059 | 4,235 |
Total current liabilities | 22,633 | 18,663 |
Noncurrent operating leases | 3,896 | 4,726 |
Other postretirement benefit obligations | 363 | 385 |
Accrued pension liabilities | 809 | 907 |
Deferred tax liabilities, net | 1,028 | 1,018 |
Other long-term liabilities | 3,403 | 4,398 |
Total liabilities | 32,132 | 30,097 |
Commitments and contingencies (Note 11) | ||
Shareholders’ equity: | ||
Common stock, $1.00 par value per share; 20,000 shares authorized; 9,082 and 8,951 shares issued and outstanding, respectively | 9,082 | 8,951 |
Additional paid-in capital | 90,532 | 89,702 |
Accumulated deficit | (7,275) | (6,810) |
Accumulated other comprehensive loss | (446) | (679) |
Total shareholders' equity | 91,893 | 91,164 |
Non-controlling interest | 62 | 35 |
Total equity | 91,955 | 91,199 |
Total liabilities and equity | $ 124,087 | $ 121,296 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) shares in Thousands, $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 |
Accounts receivable, reserves | $ 80 | $ 210 |
Common stock, par value (in dollars per share) | $ 1 | $ 1 |
Common stock, authorized (in shares) | 20,000 | 20,000 |
Common stock, issued (in shares) | 9,082 | 8,951 |
Common stock, outstanding (in shares) | 9,082 | 8,951 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | |
Cash flows from operating activities: | ||
Net income (loss) | $ (456) | $ (4,253) |
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||
Depreciation and amortization | 2,763 | 2,053 |
Equity in loss of partnerships | 112 | 71 |
Stock-based compensation | 1,019 | 1,712 |
Change in fair value of contingent consideration | 90 | 0 |
Change in allowance for doubtful accounts | (130) | 273 |
Loss on disposal of assets | 0 | 173 |
Changes in operating assets and liabilities: | ||
Accounts receivable | 682 | (260) |
Inventories | (2,642) | (3,151) |
Contract assets | (2,510) | 2,126 |
Other assets | (474) | 161 |
Accounts payable | 1,266 | (1,366) |
Accrued expenses | 2,001 | 1,912 |
Other liabilities | (385) | (959) |
Net cash provided by (used in) operating activities of continuing operations | 1,336 | (1,508) |
Net cash provided by operating activities of discontinued operation | 0 | 3 |
Net cash provided by (used in) operating activities | 1,336 | (1,505) |
Cash flows from investing activities: | ||
Purchases of property, plant and equipment | (1,300) | (1,952) |
Payments for acquisition of a business | 0 | (7,128) |
Payments for acquisition of other assets | 0 | (141) |
Purchase of investment securities | (11,965) | (6,159) |
Proceeds from maturities of investment securities | 9,885 | 15,250 |
Investment in partnerships, payments | (154) | |
Investment in partnerships, proceeds | 391 | |
Net cash (used in) provided by investing activities | (3,534) | 261 |
Cash flows from financing activities: | ||
Payment of financing leases | (18) | (57) |
Payments on liabilities for acquisition of intangible assets | (104) | 0 |
Exercise of stock options and employee stock purchase plan shares | 250 | 107 |
Withholding of common stock upon vesting of restricted stock units | (308) | (246) |
Payment of contingent consideration liabilities | (52) | 0 |
Net cash used in financing activities | (232) | (196) |
Effect of exchange rate changes on cash | (115) | (37) |
Net decrease in cash | (2,545) | (1,477) |
Cash, cash equivalents and restricted cash, beginning of period | 9,280 | 9,162 |
Cash, cash equivalents and restricted cash, end of period | 6,735 | 7,685 |
Non-cash investing and financing: | ||
Acquisition of property, plant and equipment in accounts payable | 318 | 213 |
Acquisition of a business through liabilities incurred | 0 | 3,705 |
Acquisition of a business through issuance of common stock | $ 0 | $ 982 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | AOCI Attributable to Parent [Member] | Noncontrolling Interest [Member] | Total |
Balances (in shares) at Dec. 31, 2019 | 8,781 | |||||
Balances at Dec. 31, 2019 | $ 8,781 | $ 86,770 | $ (4,286) | $ (520) | $ (253) | $ 90,492 |
Exercise of stock options, net (in shares) | 11 | |||||
Exercise of stock options, net | $ 11 | 4 | 0 | 0 | 0 | 15 |
Withholding of common stock upon vesting of restricted stock units (in shares) | 22 | |||||
Withholding of common stock upon vesting of restricted stock units | $ 22 | (220) | 0 | 0 | 0 | (198) |
Shares issued under the employee stock purchase plan (in shares) | 5 | |||||
Shares issued under the employee stock purchase plan | $ 5 | 48 | 0 | 0 | 0 | 53 |
Stock-based compensation | 0 | 376 | 0 | 0 | 0 | 376 |
Net income (loss) | 0 | 0 | (1,979) | 0 | 0 | (1,979) |
Other | $ 0 | 0 | 0 | 18 | 0 | 18 |
Balances (in shares) at Mar. 31, 2020 | 8,819 | |||||
Balances at Mar. 31, 2020 | $ 8,819 | 86,978 | (6,265) | (502) | (253) | 88,777 |
Balances (in shares) at Dec. 31, 2019 | 8,781 | |||||
Balances at Dec. 31, 2019 | $ 8,781 | 86,770 | (4,286) | (520) | (253) | 90,492 |
Net income (loss) | (4,253) | |||||
Balances (in shares) at Jun. 30, 2020 | 8,934 | |||||
Balances at Jun. 30, 2020 | $ 8,934 | 88,772 | (8,546) | (484) | (246) | 88,430 |
Balances (in shares) at Mar. 31, 2020 | 8,819 | |||||
Balances at Mar. 31, 2020 | $ 8,819 | 86,978 | (6,265) | (502) | (253) | 88,777 |
Exercise of stock options, net (in shares) | 18 | |||||
Exercise of stock options, net | $ 18 | (18) | 0 | 0 | 0 | 0 |
Withholding of common stock upon vesting of restricted stock units (in shares) | 14 | |||||
Withholding of common stock upon vesting of restricted stock units | $ 14 | (62) | 0 | 0 | 0 | (48) |
Shares issued under the employee stock purchase plan (in shares) | 3 | |||||
Shares issued under the employee stock purchase plan | $ 3 | 36 | 0 | 0 | 0 | 39 |
Stock-based compensation | 0 | 936 | 0 | 0 | 0 | 936 |
Net income (loss) | 0 | 0 | (2,281) | 0 | 7 | (2,274) |
Other | $ 0 | 0 | 0 | 18 | 0 | 18 |
Acquisition of Emerald Medical Services (in shares) | 80 | |||||
Acquisition of Emerald Medical Services | $ 80 | 902 | 0 | 0 | 0 | 982 |
Balances (in shares) at Jun. 30, 2020 | 8,934 | |||||
Balances at Jun. 30, 2020 | $ 8,934 | 88,772 | (8,546) | (484) | (246) | 88,430 |
Balances (in shares) at Dec. 31, 2020 | 8,951 | |||||
Balances at Dec. 31, 2020 | $ 8,951 | 89,702 | (6,810) | (679) | 35 | 91,199 |
Exercise of stock options, net (in shares) | 22 | |||||
Exercise of stock options, net | $ 22 | (15) | 0 | 0 | 0 | 7 |
Withholding of common stock upon vesting of restricted stock units (in shares) | 24 | |||||
Withholding of common stock upon vesting of restricted stock units | $ 24 | (265) | 0 | 0 | 0 | (241) |
Shares issued under the employee stock purchase plan (in shares) | 2 | |||||
Shares issued under the employee stock purchase plan | $ 2 | 51 | 0 | 0 | 0 | 53 |
Stock-based compensation | 0 | 453 | 0 | 0 | 0 | 453 |
Net income (loss) | 0 | 0 | 714 | 0 | (42) | 672 |
Other | $ 0 | 0 | 0 | 152 | (50) | 102 |
Balances (in shares) at Mar. 31, 2021 | 8,999 | |||||
Balances at Mar. 31, 2021 | $ 8,999 | 89,926 | (6,096) | (527) | (57) | 92,245 |
Balances (in shares) at Dec. 31, 2020 | 8,951 | |||||
Balances at Dec. 31, 2020 | $ 8,951 | 89,702 | (6,810) | (679) | 35 | $ 91,199 |
Exercise of stock options, net (in shares) | 73 | |||||
Net income (loss) | $ (456) | |||||
Balances (in shares) at Jun. 30, 2021 | 9,082 | |||||
Balances at Jun. 30, 2021 | $ 9,082 | 90,532 | (7,275) | (446) | 62 | 91,955 |
Balances (in shares) at Mar. 31, 2021 | 8,999 | |||||
Balances at Mar. 31, 2021 | $ 8,999 | 89,926 | (6,096) | (527) | (57) | 92,245 |
Exercise of stock options, net (in shares) | 41 | |||||
Exercise of stock options, net | $ 41 | 91 | 0 | 0 | 0 | 132 |
Withholding of common stock upon vesting of restricted stock units (in shares) | 39 | |||||
Withholding of common stock upon vesting of restricted stock units | $ 39 | (106) | 0 | 0 | 0 | (67) |
Shares issued under the employee stock purchase plan (in shares) | 3 | |||||
Shares issued under the employee stock purchase plan | $ 3 | 55 | 0 | 0 | 0 | 58 |
Stock-based compensation | 0 | 566 | 0 | 0 | 0 | 566 |
Net income (loss) | 0 | 0 | (1,179) | 0 | 51 | (1,128) |
Other | $ 0 | 0 | 0 | 81 | 68 | 149 |
Balances (in shares) at Jun. 30, 2021 | 9,082 | |||||
Balances at Jun. 30, 2021 | $ 9,082 | $ 90,532 | $ (7,275) | $ (446) | $ 62 | $ 91,955 |
Note 1 - Management's Statement
Note 1 - Management's Statement | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | 1. Management s Statement Intricon Corporation (together with its subsidiaries referred herein as the “Company”, or “Intricon”, “we”, “us” or “our”) is an international joint development manufacturer (“JDM”) of micromedical components, sub-assemblies and final devices. The Company serves as a JDM partner to leading medical device original equipment manufacturers (“OEMs”) by designing, developing, engineering, manufacturing, packaging and distributing micromedical products for high growth markets, such as diabetes, peripheral vascular, interventional pulmonology, electrophysiology and hearing healthcare. Our mission is to improve, extend and save lives by advancing innovative micromedical technologies through joint development and manufacturing partnerships with industry leading medical device companies. Basis of Presentation The interim condensed consolidated financial statements of the Company presented herein have been prepared by the Company and are unaudited. They have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and with instructions to Form 10 10 X. The interim condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation. The Company evaluates its voting and variable interests in entities on a qualitative and quantitative basis. The Company consolidates entities in which it concludes it has the power to direct the activities that most significantly impact an entity’s economic success and has the obligation to absorb losses or the right to receive benefits that could be significant to the entity. During the six June 30, 2021 10 December 31, 2020 Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the Company's Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2020 10 Use of Estimates The Company makes estimates and assumptions relating to the reporting of assets and liabilities, the recording of reported amounts of revenues and expenses and the disclosure of contingent assets and liabilities to prepare these condensed consolidated financial statements. Actual results could differ from those estimates. Considerable management judgment is necessary in estimating future cash flows and other factors affecting the valuation of goodwill and intangible assets, including the operating and macroeconomic factors that may Summary of Significant Accounting Policies The Company’s significant accounting policies are detailed in “Note 1: 10 December 31, 2020 |
Note 2 - New Accounting Pronoun
Note 2 - New Accounting Pronouncements | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Accounting Standards Update and Change in Accounting Principle [Text Block] | 2. New Accounting Pronouncements In June 2016, 2016 13, 326, 326 January 1, 2022 not |
Note 3 - Revenue Recognition
Note 3 - Revenue Recognition | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Revenue from Contract with Customer [Text Block] | 3. Revenue Recognition Revenue is measured based on consideration specified in the contract with a customer. Revenue from all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to a customer. For contractual arrangements in which an enforceable right exists, control of these units is deemed to transfer to the customer over time during the manufacturing process. Consequently, the transaction price is recognized as revenue over time. The transaction price for contractual arrangements without an enforceable right to payment including a reasonable margin is recognized as revenue at a point in time. The Company’s revenue recognition policy is further detailed in “Note 1: 10 December 31, 2020 During the 2021 second first six June 30, 2021. Timing of revenue recognition for the three June 30, 2021 Products and services transferred at point in time Products and services transferred over time Total Diabetes $ - $ 15,247 $ 15,247 Interventional Catheters 4,198 - 4,198 Other Medical 2,059 1,451 3,510 Value Based DTEC 950 - 950 Value Based ITEC 2,570 - 2,570 Legacy OEM 2,888 - 2,888 Professional Audio Communications 852 - 852 Total Revenue, net $ 13,517 $ 16,698 $ 30,215 Timing of revenue recognition for the six June 30, 2021 Products and services transferred at point in time Products and services transferred over time Total Diabetes $ - $ 33,611 $ 33,611 Interventional Catheters 8,000 - 8,000 Other Medical 3,649 2,819 6,468 Value Based DTEC 1,887 - 1,887 Value Based ITEC 4,555 - 4,555 Legacy OEM 5,625 - 5,625 Professional Audio Communications 1,837 - 1,837 Total Revenue, net $ 25,553 $ 36,430 $ 61,983 Timing of revenue recognition for the three June 30, 2020 Products and services transferred at point in time Products and services transferred over time Total Diabetes $ - $ 13,521 $ 13,521 Interventional Catheters 1,146 - 1,146 Other Medical 1,849 1,602 3,451 Value Based DTEC 1,387 - 1,387 Value Based ITEC 1,365 - 1,365 Legacy OEM 1,721 - 1,721 Professional Audio Communications 1,011 - 1,011 Total Revenue, net $ 8,479 $ 15,123 $ 23,602 Timing of revenue recognition for the six June 30, 2020 Products and services transferred at point in time Products and services transferred over time Total Diabetes $ - $ 27,051 $ 27,051 Interventional Catheters 1,146 - 1,146 Other Medical 3,035 3,244 6,279 Value Based DTEC 2,560 - 2,560 Value Based ITEC 2,109 - 2,109 Legacy OEM 3,685 - 3,685 Professional Audio Communications 2,275 - 2,275 Total Revenue, net $ 14,810 $ 30,295 $ 45,105 Net revenue by geography is allocated based on shipment and set forth below: Three Months Ended Six Months Ended Net Revenue by Geography June 30, 2021 June 30, 2020 June 30, 2021 June 30, 2020 United States $ 21,801 $ 17,228 $ 45,502 $ 35,016 Europe 1,676 957 2,940 2,144 Asia 4,017 2,791 7,485 4,991 All other countries 2,721 2,626 6,056 2,954 Consolidated $ 30,215 $ 23,602 $ 61,983 $ 45,105 Geographic net revenue is allocated based on the shipment location of the Company’s direct OEM customer. These customers then distribute products globally. For the three six June 30, 2021, 2020, Two June 30, 2021 December 31, 2020 Two June 30, 2021 December 31, 2020 |
Note 4 - Loss Per Share
Note 4 - Loss Per Share | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 4. Loss Per Share The following table presents a reconciliation between basic and diluted net loss per share: Three Months Ended Six Months Ended June 30, 2021 June 30, 2020 June 30, 2021 June 30, 2020 Numerator: Net loss $ (1,128 ) $ (2,274 ) $ (456 ) $ (4,253 ) Less: Income allocated to non-controlling interest 51 7 9 7 Net loss attributable to Intricon shareholders $ (1,179 ) $ (2,281 ) $ (465 ) $ (4,260 ) Denominator: Basic – weighted shares outstanding 9,074 8,881 9,034 8,847 Weighted shares assumed upon exercise of stock awards - - - - Diluted – weighted shares outstanding 9,074 8,881 9,034 8,847 Basic loss per share attributable to Intricon shareholders: $ (0.13 ) $ (0.26 ) $ (0.05 ) $ (0.48 ) Diluted loss per share attributable to Intricon shareholders: $ (0.13 ) $ (0.26 ) $ (0.05 ) $ (0.48 ) Net loss per common share was based on the weighted average number of common shares outstanding during the periods when computing basic net income per share. Stock options are dilutive when the average market price of Company stock exceeds the exercise price of the potentially dilutive options. When dilutive, stock options are included as equivalents using the treasury stock method when computing diluted net income per share. Unvested shares represented by RSUs are also included in the dilution calculation, net of assumed proceeds and equivalent share repurchases. For the three six June 30, 2021, three six June 30, 2020, |
Note 5 - Income Taxes
Note 5 - Income Taxes | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 5. Income Taxes Income tax expense for the three six June 30, 2021 2020 June 30, 2021 The following was the income (loss) before income taxes for each jurisdiction in which the Company has operations for the period: Three Months Ended Six Months Ended June 30, 2021 June 30, 2020 June 30, 2021 June 30, 2020 United States $ (1,162 ) $ (1,994 ) $ (577 ) $ (3,836 ) Singapore 77 (278 ) 215 (431 ) Indonesia 23 17 44 35 Germany 14 10 32 26 Loss before income taxes $ (1,048 ) $ (2,245 ) $ (286 ) $ (4,206 ) CARES Act On March 27, 2020, 19 not |
Note 6 - Business Combination
Note 6 - Business Combination | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Business Combination Disclosure [Text Block] | 6. Business Combination Emerald Medical Services and Emerald Extrusion Services On May 18, 2020, In addition, the Company has a 54% ownership interest in Emerald Extrusion Services LLC. (“EES), based in California. Based on this controlling financial interest, the Company has consolidated this entity. The remaining ownership is accounted for as a non-controlling interest and reported as part of equity in the condensed consolidated balance sheets. We accounted for the acquisition in accordance with ASC 805, Business Combinations, six June 30, 2021, 2021 June 30, 2021 Current assets $ 3,161 Property, plant and equipment 360 Intangible assets 6,400 Goodwill 4,321 Noncurrent assets 169 Current liabilities (1,105 ) Noncurrent liabilities (1,491 ) Total consideration paid $ 11,815 A portion of the purchase price is in the form of a contingent consideration liability calculated using a scenario-based method utilizing various level 3 3 no Quantitative information about Level 3 2: 10 December 31, 2020 no June 30, 2021 The reconciliation of the contingent consideration liability measured and carried at fair value on a recurring basis is as follows: Carrying amount at December 31, 2020 $ 3,574 Change in fair value 90 Less payments (52 ) Carrying amount at June 30, 2021 $ 3,612 Since the acquisition, the Company has paid $552 of the original contingent consideration liabilities. As of June 30, 2021, Our condensed consolidated statements of operations for the three six June 30, 2021 three six June 30, 2020 May 19 June 30, 2020. See Note 2 2020 10 |
Note 7 - Selected Balance Sheet
Note 7 - Selected Balance Sheet Data | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Supplemental Balance Sheet Disclosures [Text Block] | 7. Selected Balance Sheet Data Inventories: Inventories consisted of the following at: Raw materials Work-in process Finished products and components Total June 30, 2021 Domestic $ 12,571 $ 1,134 $ 2,756 $ 16,461 Foreign 4,265 1,137 326 5,728 Total $ 16,836 $ 2,271 $ 3,082 $ 22,189 December 31, 2020 Domestic $ 11,371 $ 1,499 $ 2,149 $ 15,019 Foreign 3,393 968 133 4,494 Total $ 14,764 $ 2,467 $ 2,282 $ 19,513 Property, Plant and Equipment Geographic Information: The geographical distribution of long-lived assets, consisting of property, plant and equipment is set forth below: June 30, December 31, 2021 2020 United States $ 12,729 $ 12,539 Singapore 1,340 1,460 Other 171 178 Consolidated $ 14,240 $ 14,177 Long-lived assets consist of property, plant and equipment. Excluded from long-lived assets are investments in partnerships, patents, goodwill, intangible assets, operating lease right-of-use (ROU) assets and certain other assets. The Company capitalizes long-lived assets pertaining to the production of specialized parts. These assets are periodically reviewed to ensure the net realizable value from the estimated future production based on forecasted cash flows exceeds the carrying value of the assets. Goodwill: During 2021, Carrying amount at December 31, 2020 $ 13,714 Purchase accounting adjustment 159 Carrying amount at June 30, 2021 $ 13,873 Intangible Assets: Definite-lived intangible assets consisted of the following at: June 30, 2021 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Customer list $ 6,400 $ (867 ) $ 5,533 Technology intangibles 6,725 (2,467 ) 4,258 Total $ 13,125 $ (3,334 ) $ 9,791 December 31, 2020 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Customer list $ 6,400 $ (467 ) $ 5,933 Technology intangibles 6,725 (1,873 ) 4,852 Total $ 13,125 $ (2,340 ) $ 10,785 The customer list was established as a part of purchase accounting related to our Emerald acquisition; see Note 6. eight The technology intangibles provide the Company with wireless and self-fitting hearing aid technology and are being amortized based on estimated useful lives between five seven Investment in Partnerships: Investment in partnerships consisted of the following: June 30, December 31, 2021 2020 Investment in Signison $ 320 $ 418 Other 272 152 Total $ 592 $ 570 The Company has a 50% ownership interest in Signison, a German based Company specializing in hearing health services. This is accounted for in the Company’s condensed consolidated financial statements using the equity method for all periods presented. Other Accrued Liabilities: Other accrued liabilities consisted of the following at: June 30, 2021 December 31, 2020 Pension and postretirement benefit obligations $ 188 $ 188 Deferred revenue 229 184 Current technology intangible liability 748 1,006 Current earn-out contingent consideration liability 1,775 1,090 Customer funded projects 550 759 TCPA litigation accrual (Note 11) 1,300 - Other 1,269 1,008 Total $ 6,059 $ 4,235 The technology intangible liability, reflected above, relates to amounts owed in relation to the Company’s wireless and self-fitting hearing aid technologies. The earn-out liability is contingent on certain future events and is measured at fair value based on various level 3 twelve 6. Other Long-Term Liabilities: Other long-term liabilities consisted of the following at: June 30, December 31, 2021 2020 Noncurrent technology intangible liability $ 667 $ 1,039 Noncurrent earn-out contingent consideration liability 1,837 2,484 Other 899 875 Total $ 3,403 $ 4,398 As of June 30, 2021 |
Note 8 - Investment Securities
Note 8 - Investment Securities | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] | 8. Investment Securities The Company invests in commercial paper, corporate notes and bonds with original maturities of less than two 2 The maturity dates of our investments as of June 30, 2021 Less than one year 1-5 years Total Commercial Paper Original Maturities of 91 Days or More $ 13,389 $ - $ 13,389 Corporate Notes and Bonds 9,633 3,794 13,427 Total Investments $ 23,022 $ 3,794 $ 26,816 The maturity dates of our investments as of December 31, 2020 Less than one year 1-5 years Total Commercial Paper Original Maturities of 91 Days or More $ 7,490 $ - $ 7,490 Corporate Notes and Bonds 12,303 5,085 17,388 Total Investments $ 19,793 $ 5,085 $ 24,878 The Company also maintains excess funds within level 1 June 30, 2021 December 31, 2020 |
Note 9 - Leases
Note 9 - Leases | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Leases of Lessee Disclosure [Text Block] | 9. Leases The Company’s leases pertain primarily to engineering, manufacturing, sales and administrative facilities, with an initial term of one three two 2022 one 2023, one 2022, two one 2022 one 2024, one 2025, one 2024, one 2022. Certain foreign leases allow for variable lease payments that depend on an index or a market rate adjustment for the respective country and are adjusted on an annual basis. The adjustment is recognized as incurred in the condensed consolidated statement of operations. The facility leases include options to extend for terms ranging from one five 2022 2024 Operating cash flows for the period ended June 30, 2021 2020 Discount rates are determined based on 5-year term incremental borrowing rates at inception of the lease. The following table summarizes the weighted-average lease term and discount rates: Weighted-Average Lease Term (Years) June 30, 2021 December 31, 2020 Finance leases 0.7 0.8 Operating leases 3.4 3.8 Weighted-Average Discount Rate June 30, 2021 December 31, 2020 Finance leases 5.56 % 5.56 % Operating leases 5.02 % 5.06 % The following tables summarizes lease costs by type: Three Months Ended Six Months Ended June 30, 2021 June 30, 2020 June 30, 2021 June 30, 2020 Lease cost Finance lease cost: Amortization of right-of-use assets $ 7 $ 26 $ 17 $ 52 Interest on lease liabilities - 1 1 3 Operating lease cost 587 393 1,169 874 Variable lease cost 119 148 239 299 Total lease cost $ 713 $ 568 $ 1,426 $ 1,228 Maturities of lease liabilities are as follows as of June 30, 2021 Operating Leases Financing Leases Total 2021 $ 1,247 $ 7 $ 1,254 2022 1,993 3 1,996 2023 1,394 - 1,394 2024 1,049 - 1,049 2025 and thereafter 776 - 776 Total lease payments 6,459 10 6,469 Less: Interest (536 ) (3 ) (539 ) Present value of lease liabilities $ 5,923 $ 7 $ 5,930 |
Note 10 - Shareholders' Equity
Note 10 - Shareholders' Equity and Stock-based Compensation | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Share-based Payment Arrangement [Text Block] | 10. Shareholders Equity and Stock-based Compensation The Company has a 2006 2015 2015 April 24, 2015, 2006 may not 2006 2006 June 30, 2021 Under the 2015 may 2015 2020 2021 2015 May 4, 2021. For the six June 30, 2021 RSUs and 15 PRSUs three first 2023 no The Company has also granted stock options under the plans. For the six June 30, 2021 2020 not three first six June 30, 2021 Stock award activity as of and during the six June 30, 2021 Outstanding Awards Stock Options RSUs Total Stock Option Weighted-Average Exercise Price (a) Aggregate Intrinsic Value Outstanding at December 31, 2020 690 217 907 $ 6.51 Awards granted - 128 128 - Awards exercised or released (73 ) (97 ) (170 ) 5.08 Outstanding at June 30, 2021 617 248 865 $ 6.68 $ 15,326 Exercisable at June 30, 2021 617 617 $ 6.68 $ 9,743 Available for future grant at December 31, 2020 73 Available for future grant at June 30, 2021 459 (a) The weighted average exercise price calculation does not The number of shares available for future grants at June 30, 2021 not 256 shares 2006 2015 2006 The Company recorded $566 and $1,019 of non-cash stock compensation expense for the three six June 30, 2021 2020 June 30, 2021 of 2. 1 years. six June 30, 2021 The Company also has an Employee Stock Purchase Plan (the “Purchase Plan”). The Purchase Plan, as amended, through June 30, 2021 may six June 30, 2021 2020 |
Note 11 - Legal Proceedings
Note 11 - Legal Proceedings | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Legal Matters and Contingencies [Text Block] | 11. Legal Proceedings Asbestos Litigation The Company is a defendant along with a number of other parties in lawsuits alleging that plaintiffs have or may one March 2005. not August 1, 1970- 1978 no 1984 not not 1970 1978 not June 30, 2021 June 30, 2021 TCPA Litigation On October 9, 2019, third not not Not four On July 26, 2021, July 28, 2021. Pursuant to the Settlement Agreement, among other things, (a) the Company has agreed to pay total cash consideration of $1.3 million into a settlement fund, and (b) Hoffman and the settlement class members agreed to a release of claims against the Company, Intricon, Inc. and HHE relating to any claim or potential claim relating to the marketing activities described in the complaint. The Settlement Agreement will become effective upon the first The $1.3 2021 second June 2021. seven no The Settlement Agreement is subject to approval by the Court. If the Court preliminarily approves the settlement, the Settlement Agreement provides for a period of time during which class members will be notified of the settlement and given an opportunity to file a claim to receive a settlement payment, opt out of the class, object to the settlement or do nothing. The Company expects that the Court will schedule a fairness hearing to occur after the notice period, at which time the parties will request final approval of the settlement and at which any objectors to the settlement will be heard. If the Court gives final approval to the settlement, the release will be effective as to all class members who do not Other Litigation Matters The Company is also involved from time to time in other lawsuits arising in the normal course of business. While it is not not |
Note 12 - Subsequent Events
Note 12 - Subsequent Events | 6 Months Ended |
Jun. 30, 2021 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 12. Subsequent Events No July 26, 2021 11. |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2021 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation The interim condensed consolidated financial statements of the Company presented herein have been prepared by the Company and are unaudited. They have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and with instructions to Form 10 10 X. The interim condensed consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation. The Company evaluates its voting and variable interests in entities on a qualitative and quantitative basis. The Company consolidates entities in which it concludes it has the power to direct the activities that most significantly impact an entity’s economic success and has the obligation to absorb losses or the right to receive benefits that could be significant to the entity. During the six June 30, 2021 10 December 31, 2020 Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the Company's Consolidated Financial Statements and Notes thereto for the fiscal year ended December 31, 2020 10 |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The Company makes estimates and assumptions relating to the reporting of assets and liabilities, the recording of reported amounts of revenues and expenses and the disclosure of contingent assets and liabilities to prepare these condensed consolidated financial statements. Actual results could differ from those estimates. Considerable management judgment is necessary in estimating future cash flows and other factors affecting the valuation of goodwill and intangible assets, including the operating and macroeconomic factors that may |
New Accounting Pronouncements, Policy [Policy Text Block] | Summary of Significant Accounting Policies The Company’s significant accounting policies are detailed in “Note 1: 10 December 31, 2020 |
Note 3 - Revenue Recognition (T
Note 3 - Revenue Recognition (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Disaggregation of Revenue [Table Text Block] | Products and services transferred at point in time Products and services transferred over time Total Diabetes $ - $ 15,247 $ 15,247 Interventional Catheters 4,198 - 4,198 Other Medical 2,059 1,451 3,510 Value Based DTEC 950 - 950 Value Based ITEC 2,570 - 2,570 Legacy OEM 2,888 - 2,888 Professional Audio Communications 852 - 852 Total Revenue, net $ 13,517 $ 16,698 $ 30,215 Products and services transferred at point in time Products and services transferred over time Total Diabetes $ - $ 33,611 $ 33,611 Interventional Catheters 8,000 - 8,000 Other Medical 3,649 2,819 6,468 Value Based DTEC 1,887 - 1,887 Value Based ITEC 4,555 - 4,555 Legacy OEM 5,625 - 5,625 Professional Audio Communications 1,837 - 1,837 Total Revenue, net $ 25,553 $ 36,430 $ 61,983 Products and services transferred at point in time Products and services transferred over time Total Diabetes $ - $ 13,521 $ 13,521 Interventional Catheters 1,146 - 1,146 Other Medical 1,849 1,602 3,451 Value Based DTEC 1,387 - 1,387 Value Based ITEC 1,365 - 1,365 Legacy OEM 1,721 - 1,721 Professional Audio Communications 1,011 - 1,011 Total Revenue, net $ 8,479 $ 15,123 $ 23,602 Products and services transferred at point in time Products and services transferred over time Total Diabetes $ - $ 27,051 $ 27,051 Interventional Catheters 1,146 - 1,146 Other Medical 3,035 3,244 6,279 Value Based DTEC 2,560 - 2,560 Value Based ITEC 2,109 - 2,109 Legacy OEM 3,685 - 3,685 Professional Audio Communications 2,275 - 2,275 Total Revenue, net $ 14,810 $ 30,295 $ 45,105 |
Revenue from External Customers by Geographic Areas [Table Text Block] | Three Months Ended Six Months Ended Net Revenue by Geography June 30, 2021 June 30, 2020 June 30, 2021 June 30, 2020 United States $ 21,801 $ 17,228 $ 45,502 $ 35,016 Europe 1,676 957 2,940 2,144 Asia 4,017 2,791 7,485 4,991 All other countries 2,721 2,626 6,056 2,954 Consolidated $ 30,215 $ 23,602 $ 61,983 $ 45,105 |
Note 4 - Loss Per Share (Tables
Note 4 - Loss Per Share (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Three Months Ended Six Months Ended June 30, 2021 June 30, 2020 June 30, 2021 June 30, 2020 Numerator: Net loss $ (1,128 ) $ (2,274 ) $ (456 ) $ (4,253 ) Less: Income allocated to non-controlling interest 51 7 9 7 Net loss attributable to Intricon shareholders $ (1,179 ) $ (2,281 ) $ (465 ) $ (4,260 ) Denominator: Basic – weighted shares outstanding 9,074 8,881 9,034 8,847 Weighted shares assumed upon exercise of stock awards - - - - Diluted – weighted shares outstanding 9,074 8,881 9,034 8,847 Basic loss per share attributable to Intricon shareholders: $ (0.13 ) $ (0.26 ) $ (0.05 ) $ (0.48 ) Diluted loss per share attributable to Intricon shareholders: $ (0.13 ) $ (0.26 ) $ (0.05 ) $ (0.48 ) |
Note 5 - Income Taxes (Tables)
Note 5 - Income Taxes (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] | Three Months Ended Six Months Ended June 30, 2021 June 30, 2020 June 30, 2021 June 30, 2020 United States $ (1,162 ) $ (1,994 ) $ (577 ) $ (3,836 ) Singapore 77 (278 ) 215 (431 ) Indonesia 23 17 44 35 Germany 14 10 32 26 Loss before income taxes $ (1,048 ) $ (2,245 ) $ (286 ) $ (4,206 ) |
Note 6 - Business Combination (
Note 6 - Business Combination (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] | Carrying amount at December 31, 2020 $ 3,574 Change in fair value 90 Less payments (52 ) Carrying amount at June 30, 2021 $ 3,612 |
Emerald Medical Services and Emerald Extrusion Services [Member] | |
Notes Tables | |
Schedule of Business Acquisitions, by Acquisition [Table Text Block] | Current assets $ 3,161 Property, plant and equipment 360 Intangible assets 6,400 Goodwill 4,321 Noncurrent assets 169 Current liabilities (1,105 ) Noncurrent liabilities (1,491 ) Total consideration paid $ 11,815 |
Note 7 - Selected Balance She_2
Note 7 - Selected Balance Sheet Data (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | Raw materials Work-in process Finished products and components Total June 30, 2021 Domestic $ 12,571 $ 1,134 $ 2,756 $ 16,461 Foreign 4,265 1,137 326 5,728 Total $ 16,836 $ 2,271 $ 3,082 $ 22,189 December 31, 2020 Domestic $ 11,371 $ 1,499 $ 2,149 $ 15,019 Foreign 3,393 968 133 4,494 Total $ 14,764 $ 2,467 $ 2,282 $ 19,513 |
Long-lived Assets by Geographic Areas [Table Text Block] | June 30, December 31, 2021 2020 United States $ 12,729 $ 12,539 Singapore 1,340 1,460 Other 171 178 Consolidated $ 14,240 $ 14,177 |
Schedule of Goodwill [Table Text Block] | Carrying amount at December 31, 2020 $ 13,714 Purchase accounting adjustment 159 Carrying amount at June 30, 2021 $ 13,873 |
Schedule of Finite-Lived Intangible Assets [Table Text Block] | June 30, 2021 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Customer list $ 6,400 $ (867 ) $ 5,533 Technology intangibles 6,725 (2,467 ) 4,258 Total $ 13,125 $ (3,334 ) $ 9,791 December 31, 2020 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Customer list $ 6,400 $ (467 ) $ 5,933 Technology intangibles 6,725 (1,873 ) 4,852 Total $ 13,125 $ (2,340 ) $ 10,785 |
Equity Method Investments [Table Text Block] | June 30, December 31, 2021 2020 Investment in Signison $ 320 $ 418 Other 272 152 Total $ 592 $ 570 |
Schedule of Accrued Liabilities [Table Text Block] | June 30, 2021 December 31, 2020 Pension and postretirement benefit obligations $ 188 $ 188 Deferred revenue 229 184 Current technology intangible liability 748 1,006 Current earn-out contingent consideration liability 1,775 1,090 Customer funded projects 550 759 TCPA litigation accrual (Note 11) 1,300 - Other 1,269 1,008 Total $ 6,059 $ 4,235 |
Other Noncurrent Liabilities [Table Text Block] | June 30, December 31, 2021 2020 Noncurrent technology intangible liability $ 667 $ 1,039 Noncurrent earn-out contingent consideration liability 1,837 2,484 Other 899 875 Total $ 3,403 $ 4,398 |
Note 8 - Investment Securities
Note 8 - Investment Securities (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Investments Classified by Contractual Maturity Date [Table Text Block] | Less than one year 1-5 years Total Commercial Paper Original Maturities of 91 Days or More $ 13,389 $ - $ 13,389 Corporate Notes and Bonds 9,633 3,794 13,427 Total Investments $ 23,022 $ 3,794 $ 26,816 Less than one year 1-5 years Total Commercial Paper Original Maturities of 91 Days or More $ 7,490 $ - $ 7,490 Corporate Notes and Bonds 12,303 5,085 17,388 Total Investments $ 19,793 $ 5,085 $ 24,878 |
Note 9 - Leases (Tables)
Note 9 - Leases (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Summary of Weighted Average Lease Term and Discount Rate [Table Text Block] | Weighted-Average Lease Term (Years) June 30, 2021 December 31, 2020 Finance leases 0.7 0.8 Operating leases 3.4 3.8 Weighted-Average Discount Rate June 30, 2021 December 31, 2020 Finance leases 5.56 % 5.56 % Operating leases 5.02 % 5.06 % |
Lease, Cost [Table Text Block] | Three Months Ended Six Months Ended June 30, 2021 June 30, 2020 June 30, 2021 June 30, 2020 Lease cost Finance lease cost: Amortization of right-of-use assets $ 7 $ 26 $ 17 $ 52 Interest on lease liabilities - 1 1 3 Operating lease cost 587 393 1,169 874 Variable lease cost 119 148 239 299 Total lease cost $ 713 $ 568 $ 1,426 $ 1,228 |
Leases Liability Maturity [Table Text Block] | Operating Leases Financing Leases Total 2021 $ 1,247 $ 7 $ 1,254 2022 1,993 3 1,996 2023 1,394 - 1,394 2024 1,049 - 1,049 2025 and thereafter 776 - 776 Total lease payments 6,459 10 6,469 Less: Interest (536 ) (3 ) (539 ) Present value of lease liabilities $ 5,923 $ 7 $ 5,930 |
Note 10 - Shareholders' Equit_2
Note 10 - Shareholders' Equity and Stock-based Compensation (Tables) | 6 Months Ended |
Jun. 30, 2021 | |
Notes Tables | |
Schedule of Stock Options Roll Forward [Table Text Block] | Outstanding Awards Stock Options RSUs Total Stock Option Weighted-Average Exercise Price (a) Aggregate Intrinsic Value Outstanding at December 31, 2020 690 217 907 $ 6.51 Awards granted - 128 128 - Awards exercised or released (73 ) (97 ) (170 ) 5.08 Outstanding at June 30, 2021 617 248 865 $ 6.68 $ 15,326 Exercisable at June 30, 2021 617 617 $ 6.68 $ 9,743 Available for future grant at December 31, 2020 73 Available for future grant at June 30, 2021 459 |
Note 1 - Management's Stateme_2
Note 1 - Management's Statement (Details Textual) | 6 Months Ended |
Jun. 30, 2021 | |
Number of Operating Segments | 1 |
Note 3 - Revenue Recognition (D
Note 3 - Revenue Recognition (Details Textual) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2021 | Mar. 31, 2021USD ($) | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | |
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | ||||||
Number of Customers | 1 | 1 | 1 | 1 | ||
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | One Customer [Member] | ||||||
Concentration Risk, Percentage | 61.00% | 61.00% | 64.00% | 62.00% | ||
Accounts Receivable [Member] | Customer Concentration Risk [Member] | ||||||
Number of Customers | 2 | 2 | ||||
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Two Customers [Member] | ||||||
Concentration Risk, Percentage | 48.00% | 69.00% | ||||
Contract Assets [Member] | Customer Concentration Risk [Member] | ||||||
Number of Customers | 2 | 2 | ||||
Revision of Prior Period, Adjustment [Member] | Revenue Reclassified From Legacy OEM to Value Based ITEC [Member] | Legacy OEM [Member] | ||||||
Revenue from Contract with Customer, Including Assessed Tax | $ (682) | |||||
Revision of Prior Period, Adjustment [Member] | Revenue Reclassified From Legacy OEM to Value Based ITEC [Member] | Hearing Health Value Based ITEC [Member] | ||||||
Revenue from Contract with Customer, Including Assessed Tax | $ 682 |
Note 3 - Revenue Recognition -
Note 3 - Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Total Revenue, net | $ 30,215 | $ 23,602 | $ 61,983 | $ 45,105 |
Diabetes [Member] | ||||
Total Revenue, net | 15,247 | 13,521 | 33,611 | 27,051 |
Interventional Catheters [Member] | ||||
Total Revenue, net | 4,198 | 1,146 | 8,000 | 1,146 |
Medical Biotelemetry Other [Member] | ||||
Total Revenue, net | 3,510 | 3,451 | 6,468 | 6,279 |
Hearing Health Direct To Consumer DTC Market [Member] | ||||
Total Revenue, net | 950 | 1,387 | 1,887 | 2,560 |
Hearing Health Value Based ITEC [Member] | ||||
Total Revenue, net | 2,570 | 1,365 | 4,555 | 2,109 |
Legacy OEM [Member] | ||||
Total Revenue, net | 2,888 | 1,721 | 5,625 | 3,685 |
Professional Audio Communications [Member] | ||||
Total Revenue, net | 852 | 1,011 | 1,837 | 2,275 |
Transferred at Point in Time [Member] | ||||
Total Revenue, net | 13,517 | 8,479 | 25,553 | 14,810 |
Transferred at Point in Time [Member] | Diabetes [Member] | ||||
Total Revenue, net | 0 | 0 | 0 | 0 |
Transferred at Point in Time [Member] | Interventional Catheters [Member] | ||||
Total Revenue, net | 4,198 | 1,146 | 8,000 | 1,146 |
Transferred at Point in Time [Member] | Medical Biotelemetry Other [Member] | ||||
Total Revenue, net | 2,059 | 1,849 | 3,649 | 3,035 |
Transferred at Point in Time [Member] | Hearing Health Direct To Consumer DTC Market [Member] | ||||
Total Revenue, net | 950 | 1,387 | 1,887 | 2,560 |
Transferred at Point in Time [Member] | Hearing Health Value Based ITEC [Member] | ||||
Total Revenue, net | 2,570 | 1,365 | 4,555 | 2,109 |
Transferred at Point in Time [Member] | Legacy OEM [Member] | ||||
Total Revenue, net | 2,888 | 1,721 | 5,625 | 3,685 |
Transferred at Point in Time [Member] | Professional Audio Communications [Member] | ||||
Total Revenue, net | 852 | 1,011 | 1,837 | 2,275 |
Transferred over Time [Member] | ||||
Total Revenue, net | 16,698 | 15,123 | 36,430 | 30,295 |
Transferred over Time [Member] | Diabetes [Member] | ||||
Total Revenue, net | 15,247 | 13,521 | 33,611 | 27,051 |
Transferred over Time [Member] | Interventional Catheters [Member] | ||||
Total Revenue, net | 0 | 0 | 0 | 0 |
Transferred over Time [Member] | Medical Biotelemetry Other [Member] | ||||
Total Revenue, net | 1,451 | 1,602 | 2,819 | 3,244 |
Transferred over Time [Member] | Hearing Health Direct To Consumer DTC Market [Member] | ||||
Total Revenue, net | 0 | 0 | 0 | 0 |
Transferred over Time [Member] | Hearing Health Value Based ITEC [Member] | ||||
Total Revenue, net | 0 | 0 | 0 | 0 |
Transferred over Time [Member] | Legacy OEM [Member] | ||||
Total Revenue, net | 0 | 0 | 0 | 0 |
Transferred over Time [Member] | Professional Audio Communications [Member] | ||||
Total Revenue, net | $ 0 | $ 0 | $ 0 | $ 0 |
Note 3 - Revenue Recognition _2
Note 3 - Revenue Recognition - Revenue By Geographic Area (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Total Revenue, net | $ 30,215 | $ 23,602 | $ 61,983 | $ 45,105 |
UNITED STATES | ||||
Total Revenue, net | 21,801 | 17,228 | 45,502 | 35,016 |
Europe [Member] | ||||
Total Revenue, net | 1,676 | 957 | 2,940 | 2,144 |
Asia [Member] | ||||
Total Revenue, net | 4,017 | 2,791 | 7,485 | 4,991 |
All Other Countries [Member] | ||||
Total Revenue, net | $ 2,721 | $ 2,626 | $ 6,056 | $ 2,954 |
Note 4 - Loss Per Share (Detail
Note 4 - Loss Per Share (Details Textual) - shares shares in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Options and Restricted Stock Units [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | 567 | 882 | 590 | 894 |
Note 4 - Loss Per Share - Earni
Note 4 - Loss Per Share - Earnings Per Share Reconciliation (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||||
Jun. 30, 2021 | Mar. 31, 2021 | Jun. 30, 2020 | Mar. 31, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Net income (loss) | $ (1,128) | $ 672 | $ (2,274) | $ (1,979) | $ (456) | $ (4,253) |
Less: Income allocated to non-controlling interest | 51 | 7 | 9 | 7 | ||
Net loss attributable to Intricon shareholders | $ (1,179) | $ (2,281) | $ (465) | $ (4,260) | ||
Basic – weighted shares outstanding (in shares) | 9,074 | 8,881 | 9,034 | 8,847 | ||
Weighted shares assumed upon exercise of stock awards (in shares) | 0 | 0 | 0 | 0 | ||
Diluted – weighted shares outstanding (in shares) | 9,074 | 8,881 | 9,034 | 8,847 | ||
Basic loss per share attributable to Intricon shareholders: (in dollars per share) | $ (0.13) | $ (0.26) | $ (0.05) | $ (0.48) | ||
Diluted loss per share attributable to Intricon shareholders: (in dollars per share) | $ (0.13) | $ (0.26) | $ (0.05) | $ (0.48) |
Note 5 - Income Taxes (Details
Note 5 - Income Taxes (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Income Tax Expense (Benefit), Total | $ 80 | $ 29 | $ 170 | $ 47 |
Note 5 - Income Taxes - Schedul
Note 5 - Income Taxes - Schedule Of Income (Loss) Before Income Taxes (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Income (loss) before income taxes | $ (1,048) | $ (2,245) | $ (286) | $ (4,206) |
Internal Revenue Service (IRS) [Member] | ||||
Income (loss) before income taxes | (1,162) | (1,994) | (577) | (3,836) |
Inland Revenue, Singapore (IRAS) [Member] | ||||
Income (loss) before income taxes | 77 | (278) | 215 | (431) |
Indonesian Tax Authority [Member] | ||||
Income (loss) before income taxes | 23 | 17 | 44 | 35 |
Federal Ministry of Finance, Germany [Member] | ||||
Income (loss) before income taxes | $ 14 | $ 10 | $ 32 | $ 26 |
Note 6 - Business Combination_2
Note 6 - Business Combination (Details Textual) - USD ($) $ in Thousands | May 18, 2020 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 |
Payment for Contingent Consideration Liability, Financing Activities | $ 52 | $ 0 | ||||
Emerald Medical Services Pte. Ltd [Member] | Emerald Extrusion Services LLC [Member] | ||||||
Equity Method Investment, Ownership Percentage | 54.00% | |||||
Emerald Medical Services Pte. Ltd [Member] | ||||||
Business Combination, Consideration Transferred, Total | $ 11,815 | |||||
Goodwill, Purchase Accounting Adjustments | 159 | |||||
Payment for Contingent Consideration Liability, Financing Activities | 52 | $ 552 | ||||
Business Combination, Contingent Consideration, Liability, Remaining Amount Contingent of Future Performance | $ 2,612 | 2,612 | $ 2,612 | |||
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual | $ 1,146 | 4,198 | 8,000 | |||
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual | $ 48 | $ 383 | $ 631 |
Note 6 - Business Combination -
Note 6 - Business Combination - Schedule of Business Acquisitions, by Acquisition (Details) - USD ($) $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 |
Goodwill | $ 13,873 | $ 13,714 |
Emerald Medical Services and Emerald Extrusion Services [Member] | ||
Current assets | 3,161 | |
Property, plant and equipment | 360 | |
Intangible assets | 6,400 | |
Goodwill | 4,321 | |
Noncurrent assets | 169 | |
Current liabilities | (1,105) | |
Noncurrent liabilities | (1,491) | |
Total consideration paid | $ 11,815 |
Note 6 - Business Combination_3
Note 6 - Business Combination - Contingent Consideration Liability (Details) - USD ($) $ in Thousands | 6 Months Ended | 13 Months Ended | |
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | |
Change in fair value | $ 90 | $ 0 | |
Less payments | (52) | $ 0 | |
Emerald Medical Services Pte. Ltd [Member] | |||
Balance | 3,574 | ||
Change in fair value | 90 | ||
Less payments | (52) | $ (552) | |
Balance | $ 3,612 | $ 3,612 |
Note 7 - Selected Balance She_3
Note 7 - Selected Balance Sheet Data (Details Textual) $ in Thousands | 6 Months Ended |
Jun. 30, 2021USD ($) | |
Long-term Line of Credit, Total | $ 0 |
Signison [Member] | |
Equity Method Investment, Ownership Percentage | 50.00% |
Customer Lists [Member] | |
Finite-Lived Intangible Asset, Useful Life (Year) | 8 years |
Technology-Based Intangible Assets [Member] | Minimum [Member] | |
Finite-Lived Intangible Asset, Useful Life (Year) | 5 years |
Technology-Based Intangible Assets [Member] | Maximum [Member] | |
Finite-Lived Intangible Asset, Useful Life (Year) | 7 years |
Note 7 - Selected Balance She_4
Note 7 - Selected Balance Sheet Data - Schedule Of Inventory (Details) - USD ($) $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 |
Raw materials | $ 16,836 | $ 14,764 |
Work-in process | 2,271 | 2,467 |
Finished products | 3,082 | 2,282 |
Inventories | 22,189 | 19,513 |
Domestic Inventories [Member] | ||
Raw materials | 12,571 | 11,371 |
Work-in process | 1,134 | 1,499 |
Finished products | 2,756 | 2,149 |
Inventories | 16,461 | 15,019 |
Foreign Inventories [Member] | ||
Raw materials | 4,265 | 3,393 |
Work-in process | 1,137 | 968 |
Finished products | 326 | 133 |
Inventories | $ 5,728 | $ 4,494 |
Note 7 - Selected Balance She_5
Note 7 - Selected Balance Sheet Data - Disclosure on Geographic Areas, Long-lived Assets in Individual Foreign Countries by Country (Details) - USD ($) $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 |
Property, plant and equipment, net | $ 14,240 | $ 14,177 |
UNITED STATES | ||
Property, plant and equipment, net | 12,729 | 12,539 |
SINGAPORE | ||
Property, plant and equipment, net | 1,340 | 1,460 |
Geographical Segments, Other [Member] | ||
Property, plant and equipment, net | $ 171 | $ 178 |
Note 7 - Selected Balance She_6
Note 7 - Selected Balance Sheet Data - Goodwill (Details) $ in Thousands | 6 Months Ended |
Jun. 30, 2021USD ($) | |
Balance | $ 13,714 |
Balance | 13,873 |
Emerald Medical Services Pte. Ltd [Member] | |
Goodwill, Purchase Accounting Adjustments | $ 159 |
Note 7 - Selected Balance She_7
Note 7 - Selected Balance Sheet Data - Finite-lived Intangible Assets (Details) - USD ($) $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 |
Carrying amount, gross | $ 13,125 | $ 13,125 |
Accumulated amortization | (3,334) | (2,340) |
Carrying amount, net | 9,791 | 10,785 |
Customer Lists [Member] | ||
Carrying amount, gross | 6,400 | 6,400 |
Accumulated amortization | (867) | (467) |
Carrying amount, net | 5,533 | 5,933 |
Technology-Based Intangible Assets [Member] | ||
Carrying amount, gross | 6,725 | 6,725 |
Accumulated amortization | (2,467) | (1,873) |
Carrying amount, net | $ 4,258 | $ 4,852 |
Note 7 - Selected Balance She_8
Note 7 - Selected Balance Sheet Data - Equity Investments (Details) - USD ($) $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 |
Investment in partnerships | $ 592 | $ 570 |
Signison [Member] | ||
Investment in partnerships | 320 | 418 |
Other Investment [Member] | ||
Investment in partnerships | $ 272 | $ 152 |
Note 7 - Selected Balance She_9
Note 7 - Selected Balance Sheet Data - Accrued Liabilities (Details) - USD ($) $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 |
Pension and postretirement benefit obligations | $ 188 | $ 188 |
Deferred revenue | 229 | 184 |
Current technology intangible liability | 748 | 1,006 |
Current earn-out contingent consideration liability | 1,775 | 1,090 |
Customer funded projects | 550 | 759 |
TCPA litigation accrual (Note 11) | 1,300 | 0 |
Other | 1,269 | 1,008 |
Total | $ 6,059 | $ 4,235 |
Note 7 - Selected Balance Sh_10
Note 7 - Selected Balance Sheet Data - Other Noncurrent Liabilities (Details) - USD ($) $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 |
Noncurrent technology intangible liability | $ 667 | $ 1,039 |
Noncurrent earn-out contingent consideration liability | 1,837 | 2,484 |
Other | 899 | 875 |
Total | $ 3,403 | $ 4,398 |
Note 8 - Investment Securitie_2
Note 8 - Investment Securities (Details Textual) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2021 | Dec. 31, 2020 | |
Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member] | ||
Cash, Ending Balance | $ 3,260 | $ 6,697 |
Maximum [Member] | ||
Maturities Benchmark for Determining Investment in Commercial Paper, Corporate Notes, and Bonds (Year) | 2 years |
Note 8 - Investment Securitie_3
Note 8 - Investment Securities - Investments Classified by Contractual Maturity Date (Details) - USD ($) $ in Thousands | Jun. 30, 2021 | Dec. 31, 2020 |
Held to maturity investments for less than one year | $ 23,022 | $ 19,793 |
Held to maturity investments for one to five years | 3,794 | 5,085 |
Held to maturity, total | 26,816 | 24,878 |
Commercial Paper Original Maturities of 91 Days or More [Member] | ||
Held to maturity investments for less than one year | 13,389 | 7,490 |
Held to maturity investments for one to five years | 0 | 0 |
Held to maturity, total | 13,389 | 7,490 |
Corporate Notes And Bonds [Member] | ||
Held to maturity investments for less than one year | 9,633 | 12,303 |
Held to maturity investments for one to five years | 3,794 | 5,085 |
Held to maturity, total | $ 13,427 | $ 17,388 |
Note 9 - Leases (Details Textua
Note 9 - Leases (Details Textual) $ in Thousands | 6 Months Ended | ||
Jun. 30, 2021USD ($) | Jun. 30, 2020USD ($) | Dec. 31, 2020USD ($) | |
Operating Lease, Right-of-Use Asset | $ 5,782 | $ 6,701 | |
Operating Lease, Liability, Total | 5,923 | ||
Operating Lease, Payments | $ 1,211 | $ 924 | |
Incremental Borrowing Rates Term for Discount Rates (Year) | 5 years | ||
Minnesota 1 [Member] | |||
Number of Leased Facilities | 3 | ||
Minnesota 1 [Member] | Lease Expiration in 2022 [Member] | |||
Number of Leased Facilities | 2 | ||
Minnesota 1 [Member] | Lease Expiration in 2023 [Member] | |||
Number of Leased Facilities | 1 | ||
Illinois 1 [Member] | |||
Number of Leased Facilities | 1 | ||
California 1 [Member] | |||
Number of Leased Facilities | 2 | ||
California 1 [Member] | Lease Expiration in 2022 [Member] | |||
Number of Leased Facilities | 1 | ||
California 1 [Member] | Lease Expiration in 2024 [Member] | |||
Number of Leased Facilities | 1 | ||
SINGAPORE | |||
Number of Leased Facilities | 1 | ||
INDONESIA | |||
Number of Leased Facilities | 1 | ||
Operating Lease, Right-of-Use Asset | $ 103 | ||
Operating Lease, Liability, Total | $ 72 | ||
GERMANY | |||
Number of Leased Facilities | 1 | ||
Minimum [Member] | |||
Lessee, Operating Lease, Term of Contract (Year) | 1 year | ||
Lessee, Operating Lease, Renewal Term (Year) | 1 year | ||
Maximum [Member] | |||
Lessee, Operating Lease, Renewal Term (Year) | 5 years |
Note 9 - Leases - Weighted Aver
Note 9 - Leases - Weighted Average Lease Term and Discount Rates (Details) | Jun. 30, 2021 | Dec. 31, 2020 |
Finance leases (Year) | 8 months 12 days | 9 months 18 days |
Operating leases (Year) | 3 years 4 months 24 days | 3 years 9 months 18 days |
Finance leases | 5.56% | 5.56% |
Operating leases | 5.02% | 5.06% |
Note 9 - Leases - Lease Cost (D
Note 9 - Leases - Lease Cost (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | |
Amortization of right-of-use assets | $ 7 | $ 26 | $ 17 | $ 52 |
Interest on lease liabilities | 0 | 1 | 1 | 3 |
Operating lease cost | 587 | 393 | 1,169 | 874 |
Variable lease cost | 119 | 148 | 239 | 299 |
Total lease cost | $ 713 | $ 568 | $ 1,426 | $ 1,228 |
Note 9 - Leases - Leases Liabil
Note 9 - Leases - Leases Liability Maturity (Details) $ in Thousands | Jun. 30, 2021USD ($) |
2021, operating lease | $ 1,247 |
2021, finance leases | 7 |
2021 | 1,254 |
2022, operating lease | 1,993 |
2022, finance leases | 3 |
2022 | 1,996 |
2023, operating lease | 1,394 |
2023, finance leases | 0 |
2023 | 1,394 |
2024, operating lease | 1,049 |
2024, finance leases | 0 |
2024 | 1,049 |
2025 and thereafter, operating lease | 776 |
2025 and thereafter, finance leases | 0 |
2025 and thereafter | 776 |
Total operating lease payments | 6,459 |
Total finance lease payments | 10 |
Total lease payments | 6,469 |
Less: Interest, operating lease | (536) |
Less: Interest, finance leases | (3) |
Less: Interest | (539) |
Operating Lease, Liability, Total | 5,923 |
Present value of finance lease liabilities | 7 |
Present value of lease liabilities | $ 5,930 |
Note 10 - Shareholders' Equit_3
Note 10 - Shareholders' Equity and Stock-based Compensation (Details Textual) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | May 04, 2021 | Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 |
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares) | 500 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 0 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) | 459 | 459 | 73 | |||
Share-based Payment Arrangement, Expense | $ 566 | $ 1,336 | $ 1,019 | $ 1,712 | ||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 3,320 | $ 3,320 | ||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 2 years 1 month 6 days | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | $ 1,333 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 300 | 300 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award (in shares) | 5 | 8 | ||||
Maximum [Member] | The 2006 Equity Incentive Plan [Member] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) | 256 | 256 | ||||
Restricted Stock Units Other than Performance Restricted Stock Units [Member] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 113 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 21.35 | |||||
Performance Restricted Stock Units [Member] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 15 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 21.78 | |||||
Restricted Stock Units (RSUs) [Member] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 128 | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 3 years | |||||
Share-based Payment Arrangement, Option [Member] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 3 years | |||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 0 | 0 | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Options Forfeitures In Order to Cover Exercise Price (in shares) | 11 | |||||
Share-based Payment Arrangement, Option [Member] | Maximum [Member] | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years |
Note 10 - Shareholders' Equit_4
Note 10 - Shareholders' Equity and Stock-based Compensation - Stock Options Roll Forward (Details) $ / shares in Units, shares in Thousands, $ in Thousands | 6 Months Ended | ||
Jun. 30, 2021USD ($)$ / sharesshares | Dec. 31, 2020shares | ||
Balance (in shares) | 690 | ||
Balance, total (in shares) | 907 | ||
Balance, weighted average exercise price (in dollars per share) | $ / shares | $ 6.51 | [1] | |
Awards granted (in shares) | 0 | ||
Awards granted, total (in shares) | 128 | ||
Awards granted, weighted average exercise price (in dollars per share) | $ / shares | $ 0 | [1] | |
Awards exercised or released (in shares) | (73) | ||
Awards exercised or released, total (in shares) | (170) | ||
Awards exercised or released (in dollars per share) | $ / shares | $ 5.08 | [1] | |
Balance (in shares) | 617 | ||
Balance, total (in shares) | 865 | ||
Balance, weighted average exercise price (in dollars per share) | $ / shares | $ 6.68 | [1] | |
Balance, intrinsic value | $ | $ 15,326 | ||
Balance, Exercisable (in shares) | 617 | ||
Exercisable, total (in shares) | 617 | ||
Exercisable, weighted average exercise price (in dollars per share) | $ / shares | $ 6.68 | [1] | |
Exercisable, intrinsic value | $ | $ 9,743 | ||
Available for future grant at December 31, 2020 (in shares) | 459 | 73 | |
Restricted Stock Units (RSUs) [Member] | |||
Balance, outstanding RSU (in shares) | 217 | ||
RSU Awards granted (in shares) | 128 | ||
RSU Awards exercised or released (in shares) | (97) | ||
Balance, outstanding RSU (in shares) | 248 | ||
[1] | The weighted average exercise price calculation does not include outstanding RSUs. |
Note 11 - Legal Proceedings (De
Note 11 - Legal Proceedings (Details Textual) - USD ($) $ in Thousands | Jul. 26, 2021 | Jun. 30, 2021 |
Settlement Agreement [Member] | Subsequent Event [Member] | ||
Litigation Settlement, Amount Awarded to Other Party | $ 1,300 | |
Minimum [Member] | ||
Potential Exposure Per Call | $ 500 | |
Maximum [Member] | ||
Potential Exposure Per Call | 1,500 | |
Other Accrued Liabilities [Member] | ||
Loss Contingency Accrual, Ending Balance | 129 | |
Other Long Term Liabilities [Member] | ||
Loss Contingency Accrual, Ending Balance | 711 | |
Other Current Assets [Member] | ||
Insurance Settlements Receivable | 129 | |
Other Assets [Member] | ||
Insurance Settlements Receivable | $ 711 |